GPC BIOTECH COMPLETES ENROLLMENT IN TRIAL FOR CANCER DRUG SATRAPLATIN

A A

GPC Biotech has completed the targeted enrollment of patients for its Phase III trial of Satraplatin for treat hormone-refractory prostate cancer. More than 200 clinical sites in fifteen countries have now accrued a total of 912 patients for the trial.

The trial, SPARC (Satraplatin and Prednisone Against Refractory Cancer), is a double-blind, randomized study that is assessing the safety and efficacy of Satraplatin in combination with prednisone as a second-line chemotherapy in patients with hormone-refractory prostate cancer.

The drug has also completed Phase II trials in ovarian cancer and small-cell lung cancer, and has started Phase II trials in breast cancer.